Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Merck
Argus Health
Cerilliant
US Department of Justice
Medtronic
Deloitte
McKesson
Colorcon

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LACTULOSE

« Back to Dashboard

Clinical Trials for Lactulose

Trial ID Title Status Sponsor Phase Summary
NCT00004796 Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis Completed Northwestern University Phase 2 OBJECTIVES: I. Assess the effect of lactulose on the circadian rhythm of plasma melatonin in patients with subclinical hepatic encephalopathy. II. Assess the intrasubject variability of circadian melatonin levels and neuropsychological tests. III. Assess which elements of the neuropsychological test battery show the response to lactulose.
NCT00004796 Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis Completed National Center for Research Resources (NCRR) Phase 2 OBJECTIVES: I. Assess the effect of lactulose on the circadian rhythm of plasma melatonin in patients with subclinical hepatic encephalopathy. II. Assess the intrasubject variability of circadian melatonin levels and neuropsychological tests. III. Assess which elements of the neuropsychological test battery show the response to lactulose.
NCT00133406 Long-term Impact and Intervention for Diarrhea in Brazil Unknown status National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 The primary objectives of this study are to determine the effect of 1 year supplementation of Vitamin A, Zinc, and Vitamin A plus Zinc compared to placebo on the Height for Age Z Score (HAZ) and the number of episodes of diarrhea and number of days of diarrhea at one year in children living in a Brazilian slum. Study participants will include 280 children ages 2 months to 8 years old, with a Height for Age Z score (HAZ) less than median for the Parque Universitario community, living in Brazilian favela. There is also a sub study to determine if ten days of glutamine delivered as an oral bolus improves the health of the digestive system.
NCT00133406 Long-term Impact and Intervention for Diarrhea in Brazil Unknown status University of Virginia Phase 3 The primary objectives of this study are to determine the effect of 1 year supplementation of Vitamin A, Zinc, and Vitamin A plus Zinc compared to placebo on the Height for Age Z Score (HAZ) and the number of episodes of diarrhea and number of days of diarrhea at one year in children living in a Brazilian slum. Study participants will include 280 children ages 2 months to 8 years old, with a Height for Age Z score (HAZ) less than median for the Parque Universitario community, living in Brazilian favela. There is also a sub study to determine if ten days of glutamine delivered as an oral bolus improves the health of the digestive system.
NCT00133562 HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition Withdrawn National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 This study will determine the effect of 7 days supplementation of alanyl-glutatime or glycine on the damaged intestinal barrier function on day 8 in children with persistent diarrhea or malnutrition.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lactulose

Condition Name

Condition Name for Lactulose
Intervention Trials
Hepatic Encephalopathy 27
Liver Cirrhosis 12
Constipation 10
Cirrhosis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lactulose
Intervention Trials
Hepatic Encephalopathy 38
Brain Diseases 37
Liver Cirrhosis 17
Fibrosis 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lactulose

Trials by Country

Trials by Country for Lactulose
Location Trials
United States 110
India 15
China 14
United Kingdom 6
Brazil 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lactulose
Location Trials
New York 10
California 6
Virginia 5
Texas 5
Massachusetts 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lactulose

Clinical Trial Phase

Clinical Trial Phase for Lactulose
Clinical Trial Phase Trials
Phase 4 28
Phase 3 14
Phase 2/Phase 3 7
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lactulose
Clinical Trial Phase Trials
Completed 52
Recruiting 19
Unknown status 13
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lactulose

Sponsor Name

Sponsor Name for Lactulose
Sponsor Trials
Valeant Pharmaceuticals International, Inc. 9
Institute of Liver and Biliary Sciences, India 6
Cumberland Pharmaceuticals 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lactulose
Sponsor Trials
Other 139
Industry 36
NIH 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Julphar
UBS
Dow
Argus Health
AstraZeneca
Cipla
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.